

§ 1271.1

- 1271.22 How and where do I register and submit an HCT/P list?
- 1271.25 What information is required for establishment registration and HCT/P listing?
- 1271.26 When must I amend my establishment registration?
- 1271.27 Will FDA assign me a registration number?
- 1271.37 Will establishment registrations and HCT/P listings be available for inspection, and how do I request information on registrations and listings?

Subpart C—Donor Eligibility

- 1271.45 What requirements does this subpart contain?
- 1271.47 What procedures must I establish and maintain?
- 1271.50 How do I determine whether a donor is eligible?
- 1271.55 What records must accompany an HCT/P after the donor-eligibility determination is complete; and what records must I maintain?
- 1271.60 What quarantine and other requirements apply before the donor-eligibility determination is complete?
- 1271.65 How do I store an HCT/P from a donor determined to be ineligible, and what uses of the HCT/P are not prohibited?
- 1271.75 How do I screen a donor?
- 1271.80 What are the general requirements for donor testing?
- 1271.85 What donor testing is required for different types of cells and tissues?
- 1271.90 Are there exceptions from the requirement of determining donor eligibility, and what labeling requirements apply?

Subpart D—Current Good Tissue Practice

- 1271.145 Prevention of the introduction, transmission, or spread of communicable diseases.
- 1271.150 Current good tissue practice requirements.
- 1271.155 Exemptions and alternatives.
- 1271.160 Establishment and maintenance of a quality program.
- 1271.170 Personnel.
- 1271.180 Procedures.
- 1271.190 Facilities.
- 1271.195 Environmental control and monitoring.
- 1271.200 Equipment.
- 1271.210 Supplies and reagents.
- 1271.215 Recovery.
- 1271.220 Processing and process controls.
- 1271.225 Process changes.
- 1271.230 Process validation.
- 1271.250 Labeling controls.
- 1271.260 Storage.
- 1271.265 Receipt, predistribution shipment, and distribution of an HCT/P.

21 CFR Ch. I (4–1–08 Edition)

- 1271.270 Records.
- 1271.290 Tracking.
- 1271.320 Complaint file.

Subpart E—Additional Requirements for Establishments Described in § 1271.10

- 1271.330 Applicability.
- 1271.350 Reporting.
- 1271.370 Labeling.

Subpart F—Inspection and Enforcement of Establishments Described in § 1271.10

- 1271.390 Applicability.
- 1271.400 Inspections.
- 1271.420 HCT/Ps offered for import.
- 1271.440 Orders of retention, recall, destruction, and cessation of manufacturing.

AUTHORITY: 42 U.S.C. 216, 243, 263a, 264, 271.

SOURCE: 66 FR 5466, Jan. 19, 2001, unless otherwise noted.

Subpart A—General Provisions

§ 1271.1 What are the purpose and scope of this part?

(a) *Purpose.* The purpose of this part, in conjunction with §§ 207.20(f), 210.1(c), 210.2, 807.20(d), and 820.1(a) of this chapter, is to create a unified registration and listing system for establishments that manufacture human cells, tissues, and cellular and tissue-based products (HCT/P's) and to establish donor-eligibility, current good tissue practice, and other procedures to prevent the introduction, transmission, and spread of communicable diseases by HCT/P's.

(b) *Scope.* (1) If you are an establishment that manufactures HCT/P's that are regulated solely under the authority of section 361 of the Public Health Service Act (the PHS Act), this part requires you to register and list your HCT/P's with the Food and Drug Administration's (FDA's) Center for Biologics Evaluation and Research and to comply with the other requirements contained in this part, whether or not the HCT/P enters into interstate commerce. Those HCT/P's that are regulated solely under the authority of section 361 of the PHS Act are described in § 1271.10.

(2) If you are an establishment that manufactures HCT/P's that are regulated as drugs, devices and/or biological products under section 351 of the PHS Act and/or the Federal Food, Drug, and Cosmetic Act, §§ 207.20(f) and

807.20(d) of this chapter require you to register and list your HCT/P's following the procedures in subpart B of this part. Sections 210.1(c), 210.2, 211.1(b), and 820.1(a) of this chapter require you to comply with the donor-eligibility procedures in subpart C of this part and the current good tissue practice procedures in subpart D of this part, in addition to all other applicable regulations.

[66 FR 5466, Jan. 19, 2001, as amended at 69 FR 29829, May 25, 2004]

§ 1271.3 How does FDA define important terms in this part?

The following definitions apply only to this part:

(a) *Autologous use* means the implantation, transplantation, infusion, or transfer of human cells or tissue back into the individual from whom the cells or tissue were recovered.

(b) *Establishment* means a place of business under one management, at one general physical location, that engages in the manufacture of human cells, tissues, and cellular and tissue-based products. "Establishment" includes:

(1) Any individual, partnership, corporation, association, or other legal entity engaged in the manufacture of human cells, tissues, and cellular and tissue-based products; and

(2) Facilities that engage in contract manufacturing services for a manufacturer of human cells, tissues, and cellular and tissue-based products.

(c) *Homologous use* means the repair, reconstruction, replacement, or supplementation of a recipient's cells or tissues with an HCT/P that performs the same basic function or functions in the recipient as in the donor.

(d) *Human cells, tissues, or cellular or tissue-based products (HCT/Ps)* means articles containing or consisting of human cells or tissues that are intended for implantation, transplantation, infusion, or transfer into a human recipient. Examples of HCT/Ps include, but are not limited to, bone, ligament, skin, dura mater, heart valve, cornea, hematopoietic stem/progenitor cells derived from peripheral and cord blood, manipulated autologous chondrocytes, epithelial cells on a synthetic matrix, and semen

or other reproductive tissue. The following articles are not considered HCT/Ps:

(1) Vascularized human organs for transplantation;

(2) Whole blood or blood components or blood derivative products subject to listing under parts 607 and 207 of this chapter, respectively;

(3) Secreted or extracted human products, such as milk, collagen, and cell factors; except that semen is considered an HCT/P;

(4) Minimally manipulated bone marrow for homologous use and not combined with another article (except for water, crystalloids, or a sterilizing, preserving, or storage agent, if the addition of the agent does not raise new clinical safety concerns with respect to the bone marrow);

(5) Ancillary products used in the manufacture of HCT/P;

(6) Cells, tissues, and organs derived from animals other than humans; and

(7) In vitro diagnostic products as defined in §809.3(a) of this chapter.

(8) Blood vessels recovered with an organ, as defined in 42 CFR 121.2, that are intended for use in organ transplantation and labeled "For use in organ transplantation only."

(e) *Manufacture means*, but is not limited to, any or all steps in the recovery, processing, storage, labeling, packaging, or distribution of any human cell or tissue, and the screening or testing of the cell or tissue donor.

(f) *Minimal manipulation means*:

(1) For structural tissue, processing that does not alter the original relevant characteristics of the tissue relating to the tissue's utility for reconstruction, repair, or replacement; and

(2) For cells or nonstructural tissues, processing that does not alter the relevant biological characteristics of cells or tissues.

(g) *Transfer* means the placement of human reproductive cells or tissues into a human recipient.

(h) *Biohazard legend* appears on the label as follows and is used to mark HCT/Ps that present a known or suspected relevant communicable disease risk.